VA gets green light to test psychedelic therapies for veteran PTSD
H.R. 7091 — Expanding Veterans’ Access to Emerging Treatments Act · Filed by Jack Bergman (R-MI) · 3 cosponsors · Introduced Jan 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the VA to establish a research program allowing veterans with conditions like PTSD, chronic pain, and substance use disorders to participate in clinical trials or access experimental treatments—including psychedelic-assisted therapies (MDMA, psilocybin, ketamine, ibogaine) and emerging medical devices—under compassionate-use protocols. The program runs for two years, with a mandatory review and the Secretary's discretion to extend or terminate.
Why we flagged it
The bill's core mechanism is authorizing the VA to conduct clinical trials and compassionate-use access for experimental treatments addressing veteran-specific conditions. It is a public-health measure aimed at expanding therapeutic options for a defined beneficiary population (veterans), not a market intervention or private carve-out.
What the text implies
- Psychedelic-assisted therapies (MDMA, psilocybin) remain Schedule I controlled substances under federal law; this bill does not change that status but authorizes VA research under investigational protocols, potentially creating a pathway for future rescheduling or regulatory change if trials show efficacy.
- The Secretary's discretion to designate 'such other treatments' and 'such other conditions' as covered creates open-ended authority to expand the program's scope without additional congressional action, subject only to the two-year sunset and Secretary's discretion to extend.
- Compassionate-use access may create demand for these therapies among veterans before FDA approval, potentially influencing future regulatory decisions or creating political pressure to approve treatments based on veteran advocacy rather than standard clinical evidence.
- The program's success or failure will be measured by a single report at one year; limited data collection or negative outcomes could be used to argue for termination, or conversely, preliminary positive results could drive rapid expansion without long-term safety data.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Veterans with treatment-resistant conditions (PTSD, chronic pain, substance use disorders) gain access to promising experimental therapies that may otherwise be unavailable to them. The program is time-limited, requires reporting, and operates within federal law, reducing risk of uncontrolled experimentation while expanding therapeutic options for a population with documented unmet needs.
Who stands to gain
- Clinical research organizations conducting VA-sponsored trials
- Pharmaceutical companies developing psychedelic-assisted therapies (MAPS, Compass Pathways, Usona In
- Medical device manufacturers (deep brain stimulation, hyperbaric oxygen therapy)
- VA medical centers and clinics designated as trial sites
Named in the bill
Department of Veterans Affairs, Secretary of Veterans Affairs, House Committee on Veterans' Affairs, Senate Committee on Veterans' Affairs, MDMA (3,4-Methylenedioxy-methamphetamine), Psilocybin, Ketamine, Ibogaine, DMT (5-Methoxy-N,N-dimethyltryptamine), 5-Methoxy-2-aminoindane, FDA (implied regulatory authority), DEA (implied controlled-substance authority)
Where it stands
3 cosponsors: 2 Republicans, 1 Democrats.
- Jan 15, 2026 — Introduced · Congress.gov: “Introduced in House”
- Jan 15, 2026 — Referred to House Committee on Veterans' Affairs · Congress.gov: “Referred to the House Committee on Veterans' Affairs”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
3 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $50,000 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 61% of bills with at least one filing.
Jack Bergman, the sponsor, reported $844,675 in PAC receipts in the 2026 cycle.
- Clearmind Medicine, Inc — $20,000 on 1 filing
- Nexalin Technology Inc. — $20,000 on 1 filing
- Adial Pharmaceuticals, Inc. — $10,000 on 1 filing
Lobbying Disclosure Act filings through Jul 18, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,957 characters) on Sep 7, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,398 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 18, 2026 · page rendered 2026-10-23.
“VA gets green light to test psychedelic therapies for veteran PTSD” QuorumCivic. https://share.quorumcivic.app/bill/119/hr7091 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.